Skip Navigation

JNCI Journal of the National Cancer Institute 1988 80(8):556-566; doi:10.1093/jnci/80.8.556
© 1988 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zalupski, M.
Right arrow Articles by Baker, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zalupski, M.
Right arrow Articles by Baker, L. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 80, No. 8, 556-566, June 15, 1988
© 1988 Oxford University Press

Ifosamide

Mark Zalupski*, Laurence H. Baker2

2Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine Detroit, MI.

*Correspondence to: Mark Zalupski, M.D., Division of Hematology and Oncology. Wayne state University School of Medicine, P.O.Box 02188, Detroit MI 48201-1998.

The alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant activity in soft tissue sarcoma and testicular carcinoma. Understanding and control of the urinary toxicity of ifosfamide therapy has allowed greater use and inclusion of ifosfamide in combinations in the treatment of malignant diseases. While preliminary results with ifosfamide in a number of diseases are encouraging, final determination of its efficacy awaits further study. A comprehensive review of preclinical data and clinical trials with ifosfamide is presented. [J Natl Cancer Inst 1988;80:556-566]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
M. Hamadani and F. Awan
Role of thiamine in managing ifosfamide-induced encephalopathy
Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 237 - 239.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. N Patel
Methylene Blue for Management of Ifosfamide-Induced Encephalopathy
Ann. Pharmacother., February 1, 2006; 40(2): 299 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C.-S. Chen, Y. Jounaidi, and D. J. Waxman
ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450
Drug Metab. Dispos., September 1, 2005; 33(9): 1261 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. P. Worden, J. M.G. Taylor, J. S. Biermann, V. K. Sondak, K. M. Leu, R. Chugh, C. J. McGinn, M. M. Zalupski, and L. H. Baker
Randomized Phase II Evaluation of 6 g/m2 of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m2 of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma
J. Clin. Oncol., January 1, 2005; 23(1): 105 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Mace, M. L. Keohan, H. Bernardy, K. Junge, G. Niebch, P. Romeis, A. Thoma, T. Wagner, U. Mueller, G. Demetri, et al.
Crossover Randomized Comparison of Intravenous versus Intravenous/Oral Mesna in Soft Tissue Sarcoma Treated with High-Dose Ifosfamide
Clin. Cancer Res., December 1, 2003; 9(16): 5829 - 5834.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frustaci, F. Gherlinzoni, A. De Paoli, M. Bonetti, A. Azzarelli, A. Comandone, P. Olmi, A. Buonadonna, G. Pignatti, E. Barbieri, et al.
Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial
J. Clin. Oncol., March 1, 2001; 19(5): 1238 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Koscielniak, D. Harms, G. Henze, H. Jurgens, H. Gadner, M. Herbst, T. Klingebiel, B. F. Schmidt, M. Morgan, R. Knietig, et al.
Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86
J. Clin. Oncol., December 1, 1999; 17(12): 3706 - 3719.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. H.C. Bramwell, W. P. Steward, M. Nooij, J. Whelan, A. W. Craft, R. J. Grimer, A. H.M. Taminau, S. R. Cannon, A. J. Malcolm, P. C.W. Hogendoorn, et al.
Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study
J. Clin. Oncol., October 1, 1999; 17(10): 3260 - 3269.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
S.A. Lakhi, E.M. Bais, E.J.T. Rutgers, and J.H. Beijnen
Hypersensitivity after ifosfamide administration
Journal of Oncology Pharmacy Practice, January 1, 1996; 2(2): 113 - 116.
[Abstract] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
J. M. Scholtz
General Principles and Pharmacology of Antineoplastic Agents
Journal of Pharmacy Practice, January 1, 1991; 4(1): 3 - 10.
[PDF]

Home page
 Journal of Pharmacy PracticeHome page
H. J. Durivage and N. L. Burnham
Prevention and Management of Toxicities Associated With Antineoplastic Drugs
Journal of Pharmacy Practice, January 1, 1991; 4(1): 27 - 48.
[PDF]

Home page
 ANN INTERN MEDHome page
M. V. Relling
Correction: Prevention of Hemorrhagic Cystitis after Cyclophosphamide
Ann Intern Med, April 15, 1990; 112(8): 634 - 634.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.